Investigating heart damage in people with HIV during heart attacks.
Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy
This study is looking at how HIV impacts heart health, especially during heart attacks, to find out why people with HIV might have more heart damage, and it hopes to discover new treatments to help protect their hearts.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10643712 on NIH RePORTER |
What this research studies
This research focuses on understanding how HIV affects heart health, particularly during heart attacks and ischemia. It aims to explore the reasons why individuals with HIV experience more severe heart damage compared to those without the virus. By using animal models, the study will investigate the role of immune system dysregulation and inflammation in worsening heart conditions. The goal is to identify potential therapies that could protect the heart from damage during these critical events.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are on antiretroviral therapy and at risk for heart disease.
Not a fit: Patients without HIV or those who do not have cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that reduce heart damage and heart failure risk in people living with HIV.
How similar studies have performed: Previous research has shown that immune dysregulation in HIV can lead to increased cardiovascular risks, suggesting that this approach could yield valuable insights.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Feinstein, Matthew Joel — Northwestern University at Chicago
- Study coordinator: Feinstein, Matthew Joel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.